The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Author： Manoharan G.   Maynard S.J.   Adgey A.J.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.5, 1999-05, pp. : 555-566

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

By  

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 103-109

Karger

Access to resources Recommend Favorite

Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

By Bosanquet N.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1135-1152

Adis International

Access to resources Recommend Favorite

Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

By Westerhout Cynthia M   Boersma Eric  

Expert Opinion on Drug Safety, Vol. 2, Iss. 1, 2003-01 ,pp. : 49-58

Informa Healthcare

Access to resources Recommend Favorite

Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1567-1570

Informa Healthcare

Access to resources Recommend Favorite

Guidance on the use of glycoprotein (GP) IIb/IIIa antagonists in the treatment of acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1357, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite